PARP inhibitor improves progression-free survival in patients with advanced breast cancers

In a randomized, Phase III trial, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.